Ramelteon is a selective melatonin receptor agonist that targets the MT1 and MT2 receptors in the brain's suprachiasmatic nucleus (SCN). By mimicking melatonin's natural effects, it helps regulate the sleep-wake cycle, primarily aiding in sleep onset. While restoring a healthy circadian rhythm is a key healthspan concept, Ramelteon's direct evidence is limited to treating the symptom of insomnia, not extending healthy lifespan.
Verdict
A targeted, non-addictive option for sleep-onset insomnia, not a general healthspan agent.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$30 - $250
Protocol
- The standard clinical dose is 8 mg taken within 30 minutes of bedtime.
- It should not be taken with or immediately after a high-fat meal.
Flags
- May cause next-day drowsiness, dizziness, or fatigue.
- Avoid use with alcohol or other CNS depressants.
- Use with caution in patients with severe liver impairment.
- Rarely, may cause complex sleep behaviors like sleep-driving.
- Can increase prolactin levels, potentially affecting hormones.